Prof. Soliman Khatib

Prof. Soliman Khatib
Principal Investigator
Associate Professor
PhD, 2001, Technion, Israel
Natural Products and Analytical Chemistry
Phone
972-50-3482174
Research interests:

 

1. Extraction, isolation, structure elucidation and synthesis of natural bioactive compounds from microalgae, plants and mushrooms for the prevention and treatment of human diseases. 

2. Analyses of endogenous molecules, oxidative-stress levels, volatile organic compounds (VOCs) and metabolomics in blood and serum using GCMS and LCMS as biomarkers for early diagnosis of human diseases such as, cardiac disease.

3. Plant metabolomics for early diagnosis of plant stress and diseases.

Natuarl bioactive compounds, Organic chemistry, Analytical chemistry and Biochemistry.

Isolation, identification and synthesis of bioactive natural compounds for the prevention and treatment of human diseases, and advanced analytical methods such as, metabolomics for early diagnosis of human and plant diseases.

  1. Reducing CVD risk by using agents that improve HDL quality. High density lipoprotein HDL has a central role in atherosclerosis inhibition due to its antiatherogenic properties such as, reverse cholesterol transport (RCT), antioxidant, anti-inflammatory, anti-apoptotic, vasodilatory and cytoprotective effects, and endothelial function improvement. In the last several years, there is growing evidence from epidemiological data, animal studies, and clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-treated, high-risk patients. However, some findings have called into question the hypothesis that pharmacologic increases in HDL cholesterol levels are necessarily beneficial. our strategy  focu on improving HDL functions (HDL “quality”) which are truly reflect and responsible for the actual beneficial effects of HDL rather than on increasing  HDL-C levels (HDL-C “quantity”) by using natural agents isolated from micro-algae and other natural plants.
  2. Production of food additives with health benefits from various kinds of algae, microalgae, plants and mushrooms. In this research we make extracts from different types of algae, microalgae, plants and mushrooms  using different types of solvents. we examine the effect of the  extracts on macrophage cells, PON1, HDL,  LDL, components associated with atherogenases, pain and inflammatory  following the isolation, characterization and identification of the active components.   
  3. Identification of blood biomarkers for the early diagnosis of diseases such as,  coronary artery disease and diabetic complication.    Our aim is to identify novel biomarkers in human blood which can predict coronary plaque status and severity. Blood levels and activities of atherogenic and antiatherogenic components will be measured, including: A) blood biochemistry clinical parameters (Blood count) B) serum metabolomics (using Orbi-Ttrap LC-MS C) , oxidative stress biomarkers such as ox-LDL level, oxysterols, linoleic acid hydroperoxide (LA-13OOH) and volatile organic compounds (VOCs), D), Serum PON1 activity, serum HDL activities and  sphingosine 1P (S1P) levels. Finally, associations between blood biomarkers and plaque status and coronary disease severity will be evaluated.  
  4. Analysis of plant secondary metabolites such as, polyphenols, flavonoids, alkaloids, cannabinoids and others using LCMS and analysis of volatile compounds such as, terpenes using GCMS. 
  5. Studying the effect of biotic and abiotic stress on the production of active secondary metabolites in cannabis plant. Our aim is to investigate the effect of biotic and abiotic stress on the development of active compounds such as, cannabinoids and terpenes in the cannabis plants. 
  6. Studying the effect of covalent and non-covalent modifications on protein properties. The proteins change their physical and biological properties due to these modifications and their covalent and non-covalent chemical interactions with the small molecules in their environment. This property of proteins that developed during the process of evolution increases proteome diversity between 10- and 100-fold. The aim of the project is to choose proteins related to atherosclerosis, such as PON1, CETP, APO-A1 and APO-B, and to examine how their biological and physical properties are affected by cavalent and noncovalent modifications that may take place within the body such as acetylation, methylation, cysteinylation, glutathionylation, oxidation, nitrosylation etc.
CV

Education

1993-1995       B.Sc., Ben-GurionUniversity, Department of Chemistry

1996-2000   Ph.D. (direct Ph.D. program), Technion – Israel Institute of Technology, Department ofChemistry

Academic and research positions

2001    Lecturer, Tel-Hai College, Department of Biotechnology

2008    Senior lecturer, Tel-Hai College, Department of Biotechnology

2019    Associate Professor, Tel-Hai College, Department of biotechnology

2001    Associate Researcher, The Oxidative Stress Research Laboratory, Migal – Galilee Research Institute.

2019    Head of the laboratory of natural compounds and analytical chemistry,  Migal – Galilee Research Institute.

2019    Scientific manager of the analytical chemistry laboratory, Tel-Hai college.

Membership in professional organizations

2002-present   Israel Society for Oxygen and Free Radicals Research  

2002-present   Israeli Society for Research, Prevention and Treatment of Atherosclerosis

Research grants

2004-2007       Israeli Science Foundation – The search for natural substrates of paraoxonase. $65,000 per year. With prof. Jacob vaya.

2004-2005       D-Cure – The effect of  PON1 on early advances glycation products. $54,000 per year. With prof. Jacob Vaya and prof. Michael Aviram.

2006                Ministry of Industry and Commerce, Chief Scientist – Screening of protein surfaces for decreased antigenicity. $130,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2007                (tashtiot) Ministry of Industry and Commerce, Chief Scientist –Screening of protein surfaces for decreased antigenicity. $150,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2007                (tashtiot) Ministry of Industry and Commerce, Chief Scientist –Enhancing the immune response and development of conjugated vaccine administrated through non-injected route. $140,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2008                (tashtiot) Ministry of Industry and Commerce, Chief Scientist – Screening of protein surfaces for decreased antigenicity. $300,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2013                Chief Scientist Office of Israel-MAGNET – New artificial NOSE (Na-NOSE) for early detection of Parkinson's disease. 129,250 NIS. With prof. Jacob Vaya, prof. John Finberg and prof. Hossam Hieck.

2014                Chief Scientist Office of Israel-MAGNET – New artificial NOSE (Na-NOSE) for early detection of Parkinson's disease. 150,368 NIS. With prof. Jacob Vaya, prof. John Finberg and prof. Hossam Hieck.

2010-2013       Ministry of Industry and Commerce, Israel – Chicken vaccination at day one.  $200,000 per year. With Dr. Elina Aizenshtein.

2015-2016       The Galilee Biomedical Research Administration, Identification of volatile organic biomarkers in blood of patients with schizophrenia, 120,000 NIS for two years. With Dr. Alon Shamir from Mazra Mental Health Center and Prof. Jacob Vaya from Migal.

2015                Chief Scientist Office of Israel-ministry of economy, Development of biologically active substances from micro-algae extracts. 397,000 NIS for one year. With Prof. Jacob Vaya and Emma Kabtinski from migal.

  2017              Migal-Galilee Research Institute, Reducing CVD risk by using natural agents that improve HDL quality. 50000 NIS.

  2018              Research grant in military medicine, Ministry of Defense, Israel, Does DPPC Characterize the active hydrophobic spots at ovine blood vessels, which are the source of bubbles nucleation on decompression? 100000 NIS.

2019-2020       Israel innovation authority, Reducing cardiovascular disease (CVD) risk by using agents. 396000 NIS/year.

2019                Jewish Colonization Association (J. C. A.) in Israel, The extraction, analysis and production of secondary metabolites from cash-crop Halophyte Sesuvium portulacastrum under salinity stress growth conditions. 100000 NIS for year.

2020-2024  Ministry of science, Cannabinoids and Terpenes-chemical composition and biology, 400, 000 for 4 years ( 100, 000 each year).

 

Scientific Publications

Ovine plasma dipalmitoylphosphatidylcholine does not predict decompression bubbling.

Arieli R., Khatib S., and Vaya J.
Respiratory Physiology & Neurobiology 2019 Volume 259 Pages 26-29
2019

Genome-wide localization of the polyphenol quercetin in human monocytes.

Atrahimovich1 D., Samson A. O., Barsheshet Y., Vaya J., Khatib S. and Reuveni A.
2019

Lyso‐diacylglyceryltrimethylhomoserine (lyso‐DGTS) isolated from Nannochloropsis microalgae improves high‐density lipoprotein (HDL) functions.

Khattib A., Atrahimovich D., Dahli L., Vaya J., and Khatib S.
2019

High-Density Lipoproteins (HDL) Composition and Function in Preeclampsia.

Einbinder Y., Biron-Shemtal T., Agassi-Zaitler M., Tzadikevich-Geffen K., Vaya J., Khatib S., Ohana M., Benchetrit S., and Zitman-Gal T.
Archives of Gynecology and Obstetrics 2018 Volume 298 Issue 2 Pages 405-413
2018

Lyso-DGTS lipid isolated from microalgae enhances PON1 activities in vitro and in vivo, increases PON1 penetration into macrophages and decreases cellular lipid accumulation.

Dahli L., Atrahimovich D., Vaya J. and Khatib S.
BioFactors 2018 Volume 44 Issue 3 Pages 299-310
2018

Nannochloropsis sp. ethanol extract prevents macrophage and LDL oxidation and enhances PON1 activity through the principal active compound lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS)

Khatib S., Artoul F., Paluy I., Boluchevsky L., Kvitnitsky E., Vaya J.
Journal of Applied Phycology 2018 Volume 30 Issue 3 Pages 1679-1689
2018

Punicalagin decreases serum glucose levels and increases PON1 activity and HDL anti-inflammatory values in Balb/c mice fed a high-fat diet

Atrahimovich D., Samson A. O., Khattib A., Vaya, J. and Khatib S.
Oxidative Medicine and Cellular Longevity 2018 Volume 2018 Issue 5 Pages 1-8
2018

Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human ??Synuclein: Comparison with Dopaminergic and Serotonergic Denervation

Finberg, J. Aluf, Y. Loboda, Y. Nakhleh, M. K Jeries, R. Aboud M. Zubedat,S. Avital,A. Khatib, K. Vaya, J. and Haick H.
ACS chemical neuroscience 2017
2017

Human carotid atherosclerotic plaque protein(s) change HDL protein(s) composition and impair HDL anti-oxidant activity.

Cohen, E., Aviram, M., Khatib, S., Volkova, N., Vaya, J.
BioFactors 2016 Volume 42 Pages 115-128
2016

Punicalagin induces serum low-density lipoprotein (LDL) influx to macrophages

Atrahimovich D., Khatib S., Vaya J., Sela S. and Samson A. O.
Oxidative Medicine and Cellular Longevity 2016 Volume 2016, Article number 7124251 Pages 9 p.
2016

Dipalmitoyl-phosphatidyl-choline from the lungs at the vascular active hydrophobic spots, which bubble on decompression

Arieli R., Khatib S. and Vaya J.
Journal of Applied Physiology 2016 Volume 121 Pages 811-815
2016

5,6-?-DHTL, a stable metabolite of arachidonic acid, is a potential substrate for paraoxonase 1

Eryanni S, Khatib S, Levi-Rosenzvig R, Tamir S, Szuchman-Sapir A
BBA Molecular and Cell Biology of Lipids 2015 Volume 1851 Pages 1118-1122
2015

Human carotid atherosclerotic lesion protein components decrease cholesterol biosynthesis rate in macrophages through 3-hydroxy-3-methylglutaryl-CoA reductase regulation

Elad Cohen., Michael Aviram., Soliman Khatib., Mira Rosenblat., Jacob Vaya
BioFactors 2015 Volume 41 Issue 1 Pages 28-34
2015

Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson?s disease

S. Khatib, J.P.M. Finberg, F. Artoul, Y. Lavner, S. Mahmood, U. Tisch, H. Haick, Y. Aluf, J. Vaya
Neurochemistry International 2014 Volume 76 Pages 82-90
2014

Human carotid plaque Phosphatidyl Choline (PC), specifically interacts with Paraoxonase1 (PON1), increases its activity and enhances its uptake by macrophage at the expense of its binding to HDL

Elad Cohen, Michael Aviram, Soliman Khatib, Fadi Artul, Asaf Rabin, Dalit Mannheim, Ron Karmeli, Tal Salamon and Jacob Vaya
Free Radical Biology and Medicine 2014 Volume 76 Pages 14-24
2014

Neural HO-1/sterol interactions in vivo: Implications for Alzheimer's disease

Hascalovici JR, Song W, Liberman A, Vaya J, Khatib S, Holcroft C, Laferla F, Schipper HM
Neuroscience 2014 Volume 280 Pages 40-49
2014

Oxysterols and symptomatic versus asymptomatic human atherosclerotic plaque

S. Khatib; J. Vaya
Biochemical and Biophysical Research Communications 2014
2014

Reduced glutathione (GSH) increases quercetin stimulatory effects on HDL- or apoA1- mediated cholesterol efflux from J774A.1 macrophages

Rosenblat M, Volkova N, Khatib S, Mahmood S, Vaya J, Aviram M.
Free Radic Res 2014 Volume 48 Issue 12 Pages 1462-1472
2014

The effect of haptens on protein-carrier immunogenicity

Gefen, T., Vaya, J., Khatib, S., Rapoport, I., Lupo, M., Dan Heller, E., Aizenshtein, E., & Pitcovski, J.
Immunology 2014 Volume 144 Pages 116-126
2014

The synthesis and analysis of S-nitorsylated paraoxonase 1

Khatib S, Artoul F, Gershko M, Markman G, Vaya J.
Biochem Biophys Res Commun 2014 Volume 444 Pages 354-359
2014